Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. The manner in which genetic and environmental factors interact to contribute to the molecular disease mechanisms has remained elusive. However, the interleukin 23 (IL-23)/T-helper 17 (T H 17) immune axis has been identified as a major immune pathway in psoriasis disease pathogenesis. Central to this pathway is the cytokine IL-23, a heterodimer composed of a p40 subunit also found in IL-12 and a p19 subunit exclusive to IL-23. IL-23 is important for maintaining T H 17 responses, and levels of IL-23 are elevated in psoriatic skin compared with non-lesional skin. A number of agents that specifically inhibit IL-23p19 are currently in development for the treatment of moderate-to-severe plaque psoriasis, with recent clinical trials demonstrating efficacy with a good safety and tolerability profile. These data support the role of this cytokine in the pathogenesis of psoriasis. A better understanding of the IL-23/T H 17 immune axis is vital and will promote the development of additional targets for psoriasis and other inflammatory diseases that share similar genetic aetiology and pathogenetic pathways.
Introduction
Psoriasis is a chronic, immune-mediated disease [1] [2] [3] affecting approximately 100 million people worldwide 4 and 2.2% of the UK population. 5 Psoriasis affects men and women of all ages 6 and can manifest in many different forms, the most common being psoriasis vulgaris (or plaque psoriasis). 4 Plaque psoriasis is characterized by patches of erythema covered in a silvery-white scale, 7 the result of rapid hyperproliferation and dysregulated differentiation of epidermal keratinocytes. 8 The aetiology of psoriasis is multifactorial and includes a complex interplay of genetic, environmental, infectious and lifestyle factors. 9, 10 Genome-wide association studies have identified numerous psoriasis-associated gene loci, [11] [12] [13] including the HLA-Cw6 gene, 14 specifically the HLA-class 1 allele, HLA-C*06:02, 13,15 located within Psoriasis Susceptibility Locus 1 (PSORS1 on 6p21.3). 16 Polymorphisms located within this gene locus confer the highest risk of psoriasis (odds ratio [OR] 4.02-16.82). 17, 18 Gene loci outside the HLA region mostly represent common genetic variants with low effect sizes, including polymorphisms in the IL-23/T H 17 immune axis such as IL12B (OR 0.78-1.15) and IL23R (OR 0.87-1.10). 11, 13, [17] [18] [19] [20] [21] Other variants, independent of HLA-C*06:02, are related to innate immune pathways, antigen presentation, and T-cell activation and differentiation. [22] [23] [24] [25] [26] [27] When combined with HLA-C*06:02, singlenucleotide polymorphisms in IL23A, IL23R, IL12B, NFKB1 and TNIP1 are associated with severe disease. 17 Overall, most of the psoriasis-associated gene loci are related to the innate and/or adaptive immune system. However, as the majority of putative causal variants are located in noncoding regions, 28 and coupled with a complex genetic environment, it remains difficult to assign individual gene variants precise roles in the pathogenesis of, and susceptibility to, psoriasis. Multiple inflammatory cell types are present in plaques, including dendritic cells (DCs), T cells and macrophages, which contribute to disease pathogenesis and drive keratinocyte proliferation. 29 T cells are known to be central to the pathogenesis of psoriasis; interfering with T-cell trafficking and cutaneous T-cell recruitment improves psoriasis. [30] [31] [32] Inhibition of CD8 + T-cell infiltration and activation into the epidermis prevented the development of psoriasis in a mouse model using human skin transplants. 33, 34 More specifically, CD4 + and CD8 + T cells with an interleukin-17 (IL-17) secretory phenotype (T-17 cells) are important contributors owing to their production of the pro-inflammatory cytokines IL-17, IL-22 and tumour necrosis factor (TNF). 35, 36 Also, a shift in the T-cell pool during psoriasis in which regulatory T cells (Tregs) begin expressing IL-17A has recently been identified. 37 Expression of the Treg master transcription factor Foxp3 is progressively lost, whereas expression of the T H 17 transcription factor retinoic acid receptor-related orphan receptor ct (RORct), is increased by Tregs. 37 This process appears to be augmented by IL-23 37 and may be a contributing factor to the chronic inflammation seen in psoriasis. DCs are also important in the pathogenesis of psoriasis owing to their influence on T-cell activation and cytokine production. Myeloid DCs (CD11c + ) are major producers of IL-23 in the skin, 38 Tip-DCs (a subset of CD11c + DCs that express inducible nitric oxide synthase) are a source of TNF, 39 and plasmacytoid DCs produce high levels of type 1 interferon (IFN). 40, 41 CD163 + -activated macrophages are also more abundant in psoriasis compared with normal skin 42 and express products typical of classically activated macrophages, including IL-23p19 and IL-12/ 23p40. 42 Although their exact role in the pathogenesis of psoriasis remains unclear, IL-17A-expressing neutrophils are known to aggregate in the epidermis, forming Munro's microabscesses in psoriatic lesions. 43 Finally, keratinocytes are a skin-specific source of IL-23 and, in health, maintain cutaneous immunity through activation of T-17 pathways. 44 It has been suggested that the localized activation and recruitment of inflammatory cells to plaques are the result of an autoimmune response in the skin. 45, 46 The human leucocyte antigen (HLA) class I allele, HLA-C*06:02, is the main risk allele in psoriasis. 17, 18 As HLA-class I molecules present peptide antigens from intracellular antigens to CD8 + T cells, a HLA-class I restricted autoimmune response must be directed against a particular target cell. 47 55 When increased expression of p40 was discovered in psoriatic lesions, this led to the initial conclusion that IL-12 expression was elevated in psoriasis. 56 However, when it was later shown that the p40 subunit of IL-12 is also found in IL-23, 57 Lee and colleagues were able to attribute the increased expression of p40 in psoriatic skin to IL-23 38 and not IL-12, as previously suggested. 56 As IL-23 is involved in the T H 17 axis, Human studies and animal models of psoriasis have confirmed the critical role of IL-23 signalling in the pathogenesis of psoriasis. For example, IL-17A and IL-17F inductions were completely abolished in IL-23p19 knock-out mice, 71 and intradermal injection of IL-23-induced skin changes was consistent with human psoriasis in wild-type mice. 63 In humans, expression of IL-23p19
messenger RNA is increased in psoriatic lesions compared with normal skin. 38 In patients with psoriasis, the IL-23 receptor is overexpressed on dermal DCs and epidermal Langerhans cells 72 ; whereas, in psoriatic lesions, IL-23 itself is overproduced by dermal DCs and keratinocytes. 38, 44, 73 In mice, nociceptors interact with dermal DCs and induce the production of IL-23, which drives skin inflammation associated with psoriasis. 74 
IL-17: a downstream effector cytokine
The IL-17 cytokine family consists of six isoforms termed IL-17 A-F. 75 Increased expression of IL-17A, E and F in psoriatic lesions has been described. [76] [77] [78] Blockade of either IL-17A or the IL-17 receptor has been shown to be an effective therapy in plaque psoriasis.
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Therapeutic targeting in psoriasis
The evolution of biologics for the treatment of psoriasis has mirrored the evolving understanding of the immunopathogenesis of the disease (Fig. 1) . Early treatment options centred on broad immunosuppression; however, as our understanding of the pathogenesis has improved, more-targeted therapies have become available.
TNF inhibitors
Efficacy of TNF blockade in psoriasis was identified in patients with inflammatory bowel disease (IBD) and psoriasis who were prescribed TNF inhibitors for the treatment of IBD. 97 These agents have proven efficacy, but their broad mechanism of action is associated with safety issues, including an increase in the risk for severe bacterial and viral infections and potentially cancer. 98, 99 Concerns regarding the safety of TNF inhibition have driven a need for new, more-targeted biologics.
IL-17A inhibitors
The first IL-17A inhibitor for the treatment of moderate-tosevere plaque psoriasis, secukinumab, was approved for the Key inflammatory effector cytokine that induces keratinocyte activation and proliferation and reduces differentiation 83, 146 Effect Activation of T H 17 cells to produce cytokines including IL-17A/F, IL-22, IL-26, IFNc, and GM-CSF, which drives the inflammatory response 64, 147 Stimulates keratinocyte expression of antimicrobial peptides (LL-37 and b-defensins), pro-inflammatory cytokines (TNF, IL-1b, IL-6) and chemokines (CXCL8-CXCL11, CCL20), which feed back into the pro-inflammatory cycle, resulting in a continued immunopathologic progression of psoriasis 145, 149 Potential consequences of blockade 113 and long-term follow-up. 114 Development of a second IL-12/23p40 antibody, briakinumab, was discontinued before all safety data were made available 115, 116 ; some speculate that this decision was associated with cardiovascular safety concerns. 117 However, meta-analyses and 
IL-23 inhibitors in development
Three inhibitors specifically targeting IL-23p19 are currently in active development for the treatment of moderate-to-severe psoriasis (Table 2) : tildrakizumab, guselkumab and risankizumab. A further antibody, LY3074828 (mirikizumab), is now entering phase 2 development. 124 Two phase 3 studies of tildrakizumab have been completed: reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754). These studies demonstrated the efficacy of tildrakizumab at Week 12 compared with placebo (reSURFACE 1 and 2) or etanercept (reSURFACE 2 only) (PASI 75: reSURFACE 1: 200 mg 62%, 100 mg 64%, placebo 6%; reSURFACE 2: 200 mg 66%, 100 mg 61%, placebo 6%, etanercept 48%; P ≤ 0.001 in all comparisons). 125 The results from the guselkumab phase 3 trials, VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), showed efficacy in treating moderate-to-severe psoriasis compared with placebo and adalimumab at Week 16 (PASI 90 [co-primary endpoint]: VOYAGE 1: guselkumab 73%, adalimumab 50%, placebo 3%; VOYAGE 2: guselkumab 70%, adalimumab 47%, placebo, 2%), Week 24 (VOYAGE 1: guselkumab 80%, adalimumab The IL-23/T H 17 immune axis in psoriasis 53%; VOYAGE 2: guselkumab 75%, adalimumab 55%), and over a 1-year period (VOYAGE 1 only: Week 48, guselkumab 76%, adalimumab 48%; P < 0.001 in all comparisons). [126] [127] [128] Phase 1 data on risankizumab in moderate-to-severe chronic plaque psoriasis (NCT01577550) reveal significant improvements in the proportion of patients achieving PASI 75 at Week 12 (PASI 75: risankizumab 87%, placebo 0%, P < 0.001) and Week 24 (risankizumab 71%, placebo 13%, P = 0.009) compared with baseline. 129 Overall, preliminary data suggest that anti-IL-23p19 agents have a favourable safety profile ( Table 3) . As the p19 subunit is exclusive to IL-23, whereas the p40 subunit is common to both IL-12 and IL-23, therapies that selectively target IL-23p19 should avoid unnecessary effects associated with IL-12/23p40 inhibition by sparing the function of IL-12. This is supported by animal data in which IL-12-deficient mice are susceptible to chemical carcinogenesis, whereas IL-23-deficient mice are resistant. 131 In patients with solid tumours, 1-year survival was significantly greater in patients with elevated serum levels of IL-12. 132 
Dosing regimens
Comparison of treatment regimens across clinical trials suggests that biologics blocking effector cytokines may require more frequent dosing compared with biologics that block upstream cytokines. Approved agents that block IL-17 require large loading doses with frequent administration within the first 4-12 weeks (secukinumab loading dose of 300 mg administered weekly for 4 weeks; ixekizumab loading dose of 160 mg administered once and 80 mg administered every 2 weeks for 12 weeks), with a reduction to one dose every 4 weeks for response maintenance. 100, 101 These dosing intervals correspond to one to two serum half-lives. 100, 101 In comparison, biologics that target IL-23 require less loading and allow a greater dosing interval for response maintenance (Table 2) , corresponding to approximately four serum half-lives. 129, 135, 136 This is probably due to differing pharmacokinetic properties and antibody affinity for IL-23p19 129, 135, 136 but might also suggest that blocking regulatory upstream cytokines may have a longer lasting effect on the pathogenic immune response in psoriasis compared with blocking effector cytokines. We propose that neutralizing IL-23 prevents the maintenance of the ongoing pathogenic T H 17 response without affecting the induction of T H 17 differentiation, which depends on IL-6 and TGF-b.
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IL-23 inhibition in other inflammatory diseases
The aetiologies of psoriasis, psoriatic arthritis and CD share several candidate genes and common pathogenetic pathways, which is not surprising considering the clinical overlap of the disorders. 26, [137] [138] [139] [140] Mutations in genes upregulated in these conditions, 
Conclusions
There is robust evidence that the IL-23/T H 17 immune axis is a key driver of psoriatic inflammation, which has led to the development of biologics that specifically target key elements of this pathway. Although there are still gaps in our understanding (Table 4) , IL-23 is now acknowledged to have a critical role in this pathway and is required for the maintenance of inflammatory T H 17 cells. Early indications from clinical trials support the use of IL-23p19-specific inhibitors as a viable treatment option that may bring additional benefits to patients with plaque psoriasis.
